DOCSLIB.ORG

(Finished Products) for All Therapeutic Categories

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(Finished Products) for All Therapeutic Categories Annex IV - Health Itemized list of items (based on DP VII and DP VIII) that may be considered for approval without circulation to the Committee A. PHARMACEUTICALS (FINISHED PRODUCTS) FOR ALL THERAPEUTIC CATEGORIES 1 CARDIOVASCULAR SYSTEM 1A DIGITALIS GLYCOSIDE 1 digoxin tab 62.5 mcg 2 digitoxin tab 100 mcg 3 digoxin tab 125 mcg 4 digoxin tab 250 mcg 5 digoxin PG elixir 50mcg /ml 6 digoxin inj 250 mcg/ml, (2ml amp) 1B DIURETICS 7 amiloride Hcl 5mg + hydrochlorthiazide 50mg tab 8 bumetanide tab 1 mg 9 chlorthalidone tab 50mg 10 ethacrynic acid as sod.salt inj powder for reconstitution 50mg vial 11 frusemide inj 20mg/2ml amp 12 frusemide IV infusion inj 10mg/ml, 25ml amp 13 frusemide tab 40mg 14 frusemide scored tab 500mg 15 frusemide oral solution pead liquid 1mg/1ml 16 frusemide oral solution 4mg/ml 17 frusemide oral solution 8mg/ml 18 hydrochlorothiazide tab 25mg 19 hydrochlorothiazide tab 50mg 20 indapamide tab 2.5mg 21 spironolactone tab 25mg 22 spironolactone tab 100mg 23 Xipamide tab 20mg 1C BETA-ADRENOCEPTER BLOCKING DRUGS 24 acebutolol tab 100mg 25 acebutolol tab 200mg 26 atenolol tab 100mg 27 atenolol tab 50mg or scored tab 28 atenolol tab 25mg 29 Bisoprolol fumarate scored tab 5mg 30 Bisoprolol fumarate scored tab 10mg 31 Carvedilol 6.25mg tab 32 Carvedilol 12.5mg tab 33 Carvedilol 25mg tab 34 Esmolol Hcl IV infusion 10mg/ml (10ml vial) 35 labetalol inj 5mg/ml (20ml amp) 36 labetalol tab 200mg 37 labetalol tab 400mg 38 metoprolol tab 50mg 39 metoprolol tab (s/r) 200mg 40 metoprolol tartrate IV inj 1mg/ml (5ml amp) 41 nadolol tab 80mg 42 oxprenolol Hcl tab 40mg 43 pindolol tab 5mg 44 propranolol Hcl slow IV inj 1mg/ml (1ml amp) 1 of 218 45 propranolol Hcl tab 10mg 46 propranolol Hcl tab (or scored tab) 40mg 47 propranolol Hcl cap (s/r) 80mg 48 sotalol tab 40mg 49 sotalol tab 80mg 1D ANTI-ARRHYTHMIC DRUGS 50 amiodarone Hcl inj 50mg/ml (3ml amp) 51 Amiodarone Hcl 200mg tab. 52 bretylium tosylate inj 50mg/ml,( 10ml amp) 53 disopyramide caps 100mg 54 disopyramide tab (s/r) durules 150mg 55 disopyramide tab retard (s/r) 250mg 56 disopyramide inj 10mg/ml, (5ml amp) 57 lignocaine Hcl slow iv infusion inj 20mg/ml, (50ml vial) plain 58 lignocaine Hcl inj 50mg/ml, (2ml amp) Spinal 59 mexiletine Hcl caps 50mg 60 mexiletine Hcl caps 200mg 61 mexiletine Hcl IV,IV infusion inj 25mg/ml, (10ml amp) 62 phenytoin sod.inj 50mg/ml, (5ml amp) 63 practolol inj 2mg/ml, (5ml amp) 64 procainamide Hcl slow IV, IV infusion inj 100mg/ml, (10ml vial) 65 procainamide Hcl tab 500mg 66 procainamide Hcl tab (s/r) 750mg 67 propafenon Hcl tab 150mg 68 quinidine Bisulfate tab (s/r) 250mg (Durules) 69 quinidine Sulphate tab 200mg 70 verapamil Hcl inj 2.5mg/ml, (2ml amp) 71 verapamil Hcl tab 40mg 72 verapamil Hcl tab 80mg 73 verapamil Hcl tab (s/r) 120mg or cap, 1E ANTI-HYPERTENSIVE DRUGS 74 alfuzosin Hcl tab 2.5mg 75 alfuzosin Hcl (S/R) tab 5mg 76 captopril tab 25mg 77 captopril tab 50mg 78 diazoxide tab 50mg 79 doxazosin scored tab 2mg 80 enalapril tab 5mg 81 enalapril tab 10mg 82 enalapril tab 20mg 83 hydralazine Hcl IV infusion inj 20mg per amp 84 hydralazine Hcl tab 25mg 85 hydralazine Hcl tab 50mg 86 Lisinopril tab 5mg 87 Lisinopril tab 10mg 88 Lisinopril tab 20mg 89 Losartan potassium tab 50mg 90 methyldopa inj 50mg/ml, (5ml amp) 91 methyldopa tab 250mg 92 minoxidil tab 5mg 93 minoxidil tab 10mg 94 phenoxybenzamine Hcl caps 10mg 95 phenoxybenzamine Hcl inj 50mg/ml, (2ml amp) 96 phentolamine mesylate inj 10mg/ml, (1ml amp) 97 prazosin Hcl tab 0.5mg 98 prazosin Hcl tab or scored tab 1mg 99 prazosin Hcl tab 2mg 100 prazosin Hcl tab 5mg 2 of 218 101 Quinapril Hcl tab 5mg 102 Quinapril Hcl tab 10mg 103 Quinapril Hcl tab 20mg 104 reserpine tab 100mcg 105 sodium nitroprusside i.v.inf 50mg per amp with solvent 106 tolazolin Hcl inj i.v 107 Valsartan cap 160mg 108 Valsartan cap 40mg 109 Valsartan cap 80mg 110 Telmisartan 40mg tab 111 Telmisartan 80mg tab 1F VASODILATORS 112 Amlodipine (as besylate) tab 2.5mg 113 Amlodipine (as besylate) tab 5mg 114 Amlodipine (as besylate) tab 10mg 115 cinnarizine tab 25mg 116 cinnarizine 75mg cap or tab 117 diltiazem Hcl tab 60mg 118 diltiazem Hcl cap (s/r) 90mg 119 diltiazem Hcl cap (s/r) 120mg 120 diltiazem Hcl IV inj or infusion 25mg/vial 121 Felodipine 5mg tab 122 glyceryl trinitrate tab 0. 5mg 123 glyceryl trinitrate inj 5mg/10ml amp. 124 glyceryl trinitrate plaster 5mg 125 glyceryl trinitrate plaster 10mg 126 glyceryl trinitrate plaster 15mg 127 glyceryl trinitrate plaster 25mg 128 glyceryl trinitrate spray 129 glyceryl trinitrate tab (c/r) 2.6mg 130 glyceryl trinitrate tab (c/r) 6.4mg 131 isosorbide dinitrate tab (s/l) 5mg 132 isosorbide dinitrate tab 10mg 133 isosorbide dinitrate tab (s/r) 20mg or cap 134 isosorbide dinitrate tab (s/r) 40mg 135 isosorbide mononitrate tab 10mg 136 isosorbide mononitrate tab or cap 20mg 137 Isosorbide mononitrate 40 mg tab 138 Isosorbide mononitrate 60 mg tab 139 isosorbide mononitrate tab(s/r)25mg or cap 140 isosorbide mononitrate tab(s/r)50mg or cap 141 Nicardipine Hcl IV inj 25mg (solution)/ amp 142 nifedipine caps 5mg 143 nifedipine caps 10mg 144 nifedipine (s/r) caps or tab 10mg 145 nifedipine caps (s/r) 20mg 146 nifedipine caps or tab (s/r) 30mg (24hr) 147 nifedipine caps (s/r) 60mg (24hr) 148 nimodipine tab 30mg 149 nimodipine i.v infusion 200mcg/ml (50ml vial) 150 oxpentiphylline tab 400mg (pentoxifylline) 151 oxpentiphylline tab 600mg (pentoxifylline) 1G SYMPATHOMIMETIC DRUGS 152 dobutamine Hcl inj 250mg per vial 153 dopamine Hcl inj 40mg/ml, (5ml amp) 154 isoprenaline Hcl inj 200 mcg/ml, (5ml amp) 155 isoprenaline Hcl tab (s/r) 20mg 156 metaraminol (as tartrate) inj 10mg/ml, (1ml amp) 3 of 218 157 methoxamine Hcl inj 20mg/ml, (1ml amp) 158 phenylephrine Hcl inj 10mg/ml, (1ml amp) 1H SCLEROSING AGENTS 159 ethanolamine oleate inj 5% 160 Sodium tetradecyl sulphate 3% (1ml amp) 1I PHOSPHODIESTERASE INHIBITORS 161 Enoximone inj 5mg/1ml (20ml amp) 2 GASTRO-INTESTINAL SYSTEM 2A ANTACIDS 162 alginic acid 500mg + mag.trisilicate 25mg + dried Al.hydroxide gel 100mg +sod.bicarb.170mg tab 163 Al.hydroxide 215mg +mag.hydroxide 80mg + simethicone 25mg/5ml susp 164 Al.hydroxide 225mg + mag.hydroxide 200mg + simethicone 25mg/5ml susp 165 Al hydroxide dried gel 475 mg tab 166 Aluminium hydroxide 140mg+mag.trisilicate 140mg+mag.carbonate 452mg (or 560mg)+bismuth subcarbonate 73mg +sod.bicarbonate 452mg +malt diastase 28mg+belladona alkaloids 70mcg(or 75mcg) /teaspoonful powder 167 co-dried mag.carb.Al.hydroxide 282 + simethicone 25mg tab 168 colloidal aluminium hydroxide tab 440mg 169 colloidal aluminium hydroxide susp 290mg/5ml, 170 dried Al.hydroxide gel 200mg +mag.hydroxide 200mg+simethicone 25mg tab 171 magnesium trisilicate powder B.P 172 Mg trisilicate 250mg+dried Al.hydroxide gel 120mg tab 173 Mg trisilicate 360mg + Al hydroxide gel 180mg tab 174 Mg trisilicate 200mg + Al hydroxide mag. carb. Co-dried gel 400mg/5ml, susp 175 Mg hydroxide 200mg + Al hydroxide (=dried gel) 225mg/5ml, susp 176 Mg hydroxide 400mg + Al hydroxide gel 400mg tab 177 oxethazaine 10mg + Al.hydroxide 300mg+ Mag.hydroxide 100mg/5ml susp 178 Pancreatin 10mg+vit B1 1mg+atropin sulphate 0.1mg+light mag.carbonate 300mg+mag.trisilicate 50mg+diastase 10mg+calc.carbonate 145mg+sod.bicarbonate 373mg+peppermint oil 0.6mg+light kaolin 50mg+dried aluminium hydroxide gel 50mg/gm powder 179 Sod. alginate 250mg+Sod. bicarb.133.5mg/5ml susp. 2B ANTISPASMODIC 180 camylofin di.Hcl tab 50mg 181 camylofin di.Hcl inj 25mg/ml 182 chlordiazepoxide 5mg + clidinium Br 2.5mg tab 183 isopropamide as iodide 5mg + trifluoperazine as Hcl 1mg tab 184 mepenzolate Br tab 25mg 185 pipenzolate Br tab 5mg 186 pipenzolate methyl Br 4mg + phenobarbital 6mg/ml drop 187 prifinium Br tab 30mg 188 prifinium Br 30mg + Paracetamol 325mg tab. 189 prifinium Br inj 7.5mg /ml 190 propantheline Br tab 15mg 2C DRUGS THAT PROMOTE HEALING OF PEPTIC ULCERS 191 bismuth chelate tab 300mg (Tri-pot. dicitrate bismuthate) 192 bismuth chelate elixir 120mg/5ml 193 cimetidine tab 200mg 194 cimetidine tab 400mg 195 Cimetidine syrup 200mg/5ml 196 cimetidine inj IV.IM ,IV infusion 100mg/ml, (2ml amp) 197 famotidine tab 20mg 198 famotidine tab (or scored tab) 40mg 199 Lansoprazole cap 15mg 200 Lansoprazole cap 30mg 201 omeprazole caps 20mg or omeprazole enteric coated tab 20mg 202 omeprazole caps 40mg or omeprazole enteric coated tab 40mg 4 of 218 203 Olsalazine sod. 250mg cap 204 pirenzepine Hcl tab 25mg 205 ranitidine tab 150mg 206 sucralfate tab 1g 207 sucralfate susp 1g/5ml 2D ANTIDIARRHOEAL DRUGS 208 codeine phosphate tab 30 mg 209 diphenoxylate Hcl 2.5mg + atropine sulphate 25mcg tab. 210 Loperamide Hcl tab 2mg 211 Sod.chloride 3.5g+Trisodium citrate dihydrate 2.9g+pot.chloride 1.5g+glucose anhydrous 20g/sachet powder (oral rehydration salts) 212 colotest kit rapid urease test for campylobactor pyloritri specialties Inc 2E TREATMENT OF CHRONIC DIARRHOES 213 mesalazine tab 400mg 214 Mesalazin foam enema 1g 215 Mesalazin rectal supp 1g 216 Mesalazin rectal supp 0.5g 217 sulphasalazine 500mg E.N tab 218 Sod.cromoglycate (oral only) cap 100mg 2F LAXATIVES 219 bisacodyl supp 5mg (child) 220 bisacodyl supp 10mg (adult) 221 bisacodyl tab 5mg 222 bran tab 2g 223 Calcium-salt of purified senna-containing 12g of senna glycoside tab 224 castor oil, 200ml 225 dioctyl Sod.
Load more

Recommended publications
  • Integrating Complementary Medicine Into Cardiovascular Medicine
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Journal of the American College of Cardiology Vol. 46, No. 1, 2005 © 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.031 ACCF COMPLEMENTARY MEDICINE EXPERT CONSENSUS DOCUMENT Integrating Complementary Medicine Into Cardiovascular Medicine A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine) WRITING COMMITTEE MEMBERS JOHN H. K. VOGEL, MD, MACC, Chair STEVEN F. BOLLING, MD, FACC BRIAN OLSHANSKY, MD, FACC REBECCA B. COSTELLO, PHD KENNETH R. PELLETIER, MD(HC), PHD ERMINIA M. GUARNERI, MD, FACC CYNTHIA M. TRACY, MD, FACC MITCHELL W. KRUCOFF, MD, FACC, FCCP ROBERT A. VOGEL, MD, FACC JOHN C. LONGHURST, MD, PHD, FACC TASK FORCE MEMBERS ROBERT A. VOGEL, MD, FACC, Chair JONATHAN ABRAMS, MD, FACC SANJIV KAUL, MBBS, FACC JEFFREY L. ANDERSON, MD, FACC ROBERT C. LICHTENBERG, MD, FACC ERIC R. BATES, MD, FACC JONATHAN R. LINDNER, MD, FACC BRUCE R. BRODIE, MD, FACC* ROBERT A. O’ROURKE, MD, FACC† CINDY L. GRINES, MD, FACC GERALD M. POHOST, MD, FACC PETER G. DANIAS, MD, PHD, FACC* RICHARD S. SCHOFIELD, MD, FACC GABRIEL GREGORATOS, MD, FACC* SAMUEL J. SHUBROOKS, MD, FACC MARK A. HLATKY, MD, FACC CYNTHIA M. TRACY, MD, FACC* JUDITH S. HOCHMAN, MD, FACC* WILLIAM L. WINTERS, JR, MD, MACC* *Former members of Task Force; †Former chair of Task Force The recommendations set forth in this report are those of the Writing Committee and do not necessarily reflect the official position of the American College of Cardiology Foundation.
    [Show full text]
  • Synthesis, Physicochemical Characterization and Study of the Antimicrobial Activity of Chlorobutanol H
    World Academy of Science, Engineering and Technology International Journal of Pharmacological and Pharmaceutical Sciences Vol:12, No:3, 2018 Synthesis, Physicochemical Characterization and Study of the Antimicrobial Activity of Chlorobutanol H. Nadia, G. Bahdja, S. Thili Malha, Y. Zahoua, D. Taoufik, B. Mourad, M. Marzouk, F. Z. Hadjadj Aoul, L. R. Mekacher I. INTRODUCTION Abstract—Introduction and objectives: Chlorobutanol is a raw XCIPIENTS play a vital role in the design, manufacture material, mainly used as an antiseptic and antimicrobial preservative and preservation of drugs. The addition of an in injectable and ophthalmic preparations. The main objective of our E study was the synthesis and evaluation of the antimicrobial activity of antimicrobial agents is of great interest in the case where the chlorobutanol hemihydrates. Material and methods: Chlorobutanol pharmaceutical preparations do not have adequate was synthesized according to the nucleophilic addition reaction of antimicrobial properties, (especially aqueous preparations), to chloroform to acetone, identified by an infrared absorption using prevent proliferation or limit microbial contamination [1], [2]. Spectrum One FTIR spectrometer, melting point, Scanning electron Chlorobutanol is a trihalogen alcohol with bacteriostatic and microscopy and colorimetric reactions. The dosage of Carvedilol fungistatic activity. The main objective of our work was to active substance was carried out by assaying the degradation products of chlorobutanol in a basic solution. The chlorobutanol obtained was obtain chlorobutanol hemihydrate by chemical synthesis, its subjected to bacteriological tests in order to study its antimicrobial purification and characterization as well as the study of its activity. The antibacterial activity was evaluated against strains such antimicrobial activity. as Escherichia coli (ATCC 25 922), Staphylococcus aureus (ATCC 25 923) and Pseudomonas aeroginosa (ATCC = American type II.
    [Show full text]
  • Appendix on Tariff Elimination Schedule for Mercosur
    Trade part of the EU-Mercosur Association Agreement Without Prejudice Disclaimer: In view of the Commission's transparency policy, the Commission is publishing the texts of the Trade Part of the Agreement following the agreement in principle announced on 28 June 2019. The texts are published for information purposes only and may undergo further modifications including as a result of the process of legal revision. However, in view of the growing public interest in the negotiations, the texts are published at this stage of the negotiations for information purposes. These texts are without prejudice to the final outcome of the agreement between the EU and Mercosur. The texts will be final upon signature. The agreement will become binding on the Parties under international law only after completion by each Party of its internal legal procedures necessary for the entry into force of the Agreement (or its provisional application). AR applied BR applied PY applied UY applied Mercosur Final NCM Description Comments tariff tariff tariff tariff Offer 01012100 Pure-bred horses 0 0 0 0 0 01012900 Lives horses, except pure-bred breeding 2 2 2 2 0 01013000 Asses, pure-bred breeding 4 4 4 4 4 01019000 Asses, except pure-bred breeding 4 4 4 4 4 01022110 Purebred breeding cattle, pregnant or lactating 0 0 0 0 0 01022190 Other pure-bred cattle, for breeding 0 0 0 0 0 01022911 Other bovine animals for breeding,pregnant or lactating 2 2 2 2 0 01022919 Other bovine animals for breeding 2 2 2 2 4 01022990 Other live catlle 2 2 2 2 0 01023110 Pure-bred breeding buffalo, pregnant or lactating 0 0 0 0 0 01023190 Other pure-bred breeding buffalo 0 0 0 0 0 01023911 Other buffalo for breeding, ex.
    [Show full text]
  • Penetration of Synthetic Corticosteroids Into Human Aqueous Humour
    Eye (1990) 4, 526--530 Penetration of Synthetic Corticosteroids into Human Aqueous Humour C. N. 1. McGHEE,1.3 D. G. WATSON, 3 1. M. MIDGLEY, 3 M. 1. NOBLE, 2 G. N. DUTTON, z A. I. FERNl Glasgow Summary The penetration of prednisolone acetate (1%) and fluorometholone alcohol (0.1%) into human aqueous humour following topical application was determined using the very sensitive and specific technique of Gas Chromatography with Mass Spec­ trometry (GCMS). Prednisolone acetate afforded peak mean concentrations of 669.9 ng/ml within two hours and levels of 28.6 ng/ml in aqueous humour were detected almost 24 hours post application. The peak aqueous humour level of flu­ orometholone was S.lng/ml. The results are compared and contrasted with the absorption of dexamethasone alcohol (0.1%), betamethasone sodium phosphate (0.1 %) and prednisolone sodium phosphate (0.5%) into human aqueous humour. Topical corticosteroid preparations have been prednisolone acetate (1.0%) and fluorometh­ used widely in ophthalmology since the early alone alcohol (0.1 %) (preliminary results) 1960s and over the last 10 years the choice of into the aqueous humour of patients under­ preparations has become larger and more going elective cataract surgery. varied. Unfortunately, data on the intraocular penetration of these steroids in humans has SUbjects and Methods not paralleled the expansion in the number of Patients who were scheduled to undergo rou­ available preparations; indeed until recently, tine cataract surgery were recruited to the estimation of intraocular penetration has study and informed consent was obtained in been reliant upon extrapolation of data from all cases (n=88), Patients with corneal disease animal models (see Watson et ai., 1988, for or inflammatory ocular conditions which bibliography).
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Butenafine Hydrochloride/Climbazole 529 to Be Reduced in Patients with Hepatic Impairment (See Profile Solution in Water Has a Ph of 8.0 to 9.0
    Butenafine Hydrochloride/Climbazole 529 to be reduced in patients with hepatic impairment (see Profile solution in water has a pH of 8.0 to 9.0. Protect from light. below). Chlormidazole hydrochloride is an imidazole antifungal used USP 31 (Ciclopirox Olamine). A white to slightly yellowish- topically as the hydrochloride in the treatment of fungal infec- white, crystalline powder. Slightly soluble in water; very soluble ◊ Reviews. tions of the skin. in alcohol and in dichloromethane; practically insoluble in cy- 1. Letscher-Bru V, Herbrecht R. Caspofungin: the first representa- For a discussion of the caution needed when using azole antifun- clohexane. pH of a 1% solution in water is between 8.0 and 9.0. tive of a new antifungal class. J Antimicrob Chemother 2003; 51: gals during pregnancy, see under Pregnancy in Precautions of Store in airtight containers at a temperature of 5° to 25°. Protect 513–21. Fluconazole, p.532. from light. 2. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36: 1445–57. Preparations Adverse Effects 3. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: Proprietary Preparations (details are given in Part 3) Irritation and pruritus have been reported after topical applica- 1142–51. Pol.: Unifungicid. tion of ciclopirox. 4. McCormack PL, Perry CM. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 2005; 65: 2049–68. Multi-ingredient: Austria: Myco-Synalar; Pol.: Polfungicid; Switz.: Antimicrobial Action 5. Morris MI, Villmann M. Echinocandins in the management of Myco-Synalar†. Ciclopirox has a wide spectrum of antifungal activity. It inhibits invasive fungal infections, part 1.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Infant Antibiotic Exposure Search EMBASE 1. Exp Antibiotic Agent/ 2
    Infant Antibiotic Exposure Search EMBASE 1. exp antibiotic agent/ 2. (Acedapsone or Alamethicin or Amdinocillin or Amdinocillin Pivoxil or Amikacin or Aminosalicylic Acid or Amoxicillin or Amoxicillin-Potassium Clavulanate Combination or Amphotericin B or Ampicillin or Anisomycin or Antimycin A or Arsphenamine or Aurodox or Azithromycin or Azlocillin or Aztreonam or Bacitracin or Bacteriocins or Bambermycins or beta-Lactams or Bongkrekic Acid or Brefeldin A or Butirosin Sulfate or Calcimycin or Candicidin or Capreomycin or Carbenicillin or Carfecillin or Cefaclor or Cefadroxil or Cefamandole or Cefatrizine or Cefazolin or Cefixime or Cefmenoxime or Cefmetazole or Cefonicid or Cefoperazone or Cefotaxime or Cefotetan or Cefotiam or Cefoxitin or Cefsulodin or Ceftazidime or Ceftizoxime or Ceftriaxone or Cefuroxime or Cephacetrile or Cephalexin or Cephaloglycin or Cephaloridine or Cephalosporins or Cephalothin or Cephamycins or Cephapirin or Cephradine or Chloramphenicol or Chlortetracycline or Ciprofloxacin or Citrinin or Clarithromycin or Clavulanic Acid or Clavulanic Acids or clindamycin or Clofazimine or Cloxacillin or Colistin or Cyclacillin or Cycloserine or Dactinomycin or Dapsone or Daptomycin or Demeclocycline or Diarylquinolines or Dibekacin or Dicloxacillin or Dihydrostreptomycin Sulfate or Diketopiperazines or Distamycins or Doxycycline or Echinomycin or Edeine or Enoxacin or Enviomycin or Erythromycin or Erythromycin Estolate or Erythromycin Ethylsuccinate or Ethambutol or Ethionamide or Filipin or Floxacillin or Fluoroquinolones
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • The Role of Antispasmodics in Managing Irritable Bowel Syndrome
    DOI: https://doi.org/10.22516/25007440.309 Review articles The role of antispasmodics in managing irritable bowel syndrome Valeria Atenea Costa Barney,1* Alan Felipe Ovalle Hernández.1 1 Internal Medicine and Gastroenterology specialist Abstract in San Ignacio University Hospital, Pontificia Universidad Javeriana, Bogotá, Colombia. Although antispasmodics are the cornerstone of treating irritable bowel syndrome, there are a number of an- tispasmodic medications currently available in Colombia. Since they are frequently used to treat this disease, *Correspondence: [email protected] we consider an evaluation of them to be important. ......................................... Received: 26/10/18 Keywords Accepted: 11/02/19 Antispasmodic, irritable bowel syndrome, pinaverium bromide, otilonium bromide, Mebeverin, trimebutine. INTRODUCTION consistency. The criteria must be met for three consecutive months prior to diagnosis and symptoms must have started Irritable bowel syndrome (IBS) is one of the most fre- a minimum of six months before diagnosis. (3, 4) quent chronic gastrointestinal functional disorders. It is There are no known structural or anatomical explanations characterized by recurrent abdominal pain associated with of the pathophysiology of IBS and its exact cause remains changes in the rhythm of bowel movements with either or unknown. Nevertheless, several mechanisms have been both constipation and diarrhea. Swelling and bloating are proposed. Altered gastrointestinal motility may contribute frequent occurrences. (1) to changes in bowel habits reported by some patients, and a IBS is divided into two subtypes: predominance of cons- combination of smooth muscle spasms, visceral hypersen- tipation (20-30% of patients) and predominance of dia- sitivity and abnormalities of central pain processing may rrhea (20-30% of patients).
    [Show full text]